Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA to reconsider decision barring compounded versions of Lilly weight loss drug
FDA to reconsider decision barring compounded versions of Lilly weight loss drug
FDA to reconsider decision barring compounded versions of Lilly weight loss drug
Submitted by
admin
on October 13, 2024 - 11:33am
Source:
Reuters
News Tags:
FDA
Eli Lilly
compounded drugs
drug shortages
obesity drugs
tirzepatide
Headline:
FDA to reconsider decision barring compounded versions of Lilly weight loss drug
snippet:
FDA to review if there's a shortage of tirzepatide
Outsourcing Facilities Association lawsuit led to FDA reconsideration
Shortages of Lilly and Novo Nordisk drugs drive demand for compounded versions
Do Not Allow Advertisers to Use My Personal information
